Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.50 |
| ▸ | RPS6KB2 | Q9UBS0 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8381542 | 0.94 | ADORA2A (0.50) | ADORA2AADORA1RPS6KB2LMNAMAPK1 | |
| SCHEMBL15958601 | 0.84 | ADORA2A (0.54) | ADORA2AADORA1RPS6KB2LMNAKDM4E | |
| SCHEMBL8380271 | 0.84 | RPS6KB2 (0.49) | ADORA2AADORA1RPS6KB2LMNAMAPK1 | |
| SCHEMBL13595005 | 0.82 | RPS6KB2 (0.46) | ADORA2AADORA1RPS6KB2LMNAMAPK1 | |
| SCHEMBL15958680 | 0.81 | RAB9A (0.52) | ADORA2AADORA1RPS6KB2LMNAMAPK1 | |
| SCHEMBL7917553 | 0.81 | ADORA2A (0.44) | ADORA2AADORA1RPS6KB2LMNANPSR1 | |
| SCHEMBL13595008 | 0.80 | PGK1 (0.53) | ADORA2AADORA1RPS6KB2LMNAKDM4E | |
| SCHEMBL14164355 | 0.78 | RPS6KB2 (0.59) | ADORA2AADORA1RPS6KB2LMNAKDM4E | |
| SCHEMBL8381274 | 0.78 | ADORA2A (0.45) | ADORA2AADORA1RPS6KB2LMNAMAPK1 | |
| SCHEMBL8380549 | 0.78 | ADORA2A (0.42) | ADORA2AADORA1RPS6KB2LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910587-B2 | Quinoxalinyl dipeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-7635683-B2 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20090005387-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20080267918-A1 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | ADORA2A 3329/4885ADORA1 3382/4885RPS6KB2 4248/4885 |
| US-20090005387-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, CTSC | ADORA2A 4027/4885ADORA1 3873/4885RPS6KB2 4346/4885 |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | PRSS1, SPINT2, CTSC | ADORA2A 4027/4885ADORA1 3873/4885RPS6KB2 4346/4885 |
| US-20080267918-A1 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS | DPP4, CTSC, PEPD | ADORA2A 3683/4885ADORA1 3047/4885RPS6KB2 4618/4885 |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | VIP, CTSC, PREP | ADORA2A 4080/4885ADORA1 3511/4885RPS6KB2 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.